ID
45842
Description
Principal Investigator: Steven McCarroll, PhD, The Broad Institute of MIT and Harvard, Cambridge, MA, USA MeSH: Schizophrenia,Bipolar Disorder https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001020 The Center for Genomic Psychiatry at the University of Southern California (USC), SUNY Downstate and an extensive network of academic medical centers have created the Genomic Psychiatry Cohort (GPC). The GPC consists of a large clinical cohort of patients with schizophrenia, bipolar disorder, and healthy controls. The data generation of genotyping and whole genome sequencing of the GPC has been done in collaboration with the USC and the Broad Institute of MIT and Harvard. Genome-wide association studies are being performed with the samples to identify genetic risks for psychiatric disease. Genotyping is also being used to determine ancestry informative markers and replication of candidate genes. Whole genome sequencing identifies functional variants associated with disease risk.
Lien
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001020
Mots-clés
Versions (1)
- 24/08/2023 24/08/2023 - Arman Ghanaat
Détendeur de droits
Steven McCarroll, PhD, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
Téléchargé le
24 août 2023
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
dbGaP phs001020 Genomic Psychiatry Cohort (GPC) Whole Genome Sequencing and Genotyping Study
This sample attributes table informs of body site where sample was collected, sample analyte type, sample tumor status, sample histology, whether 30X mean coverage was achieved in the sample during sequencing, and site where sequencing took place.
- StudyEvent: SEV1
- Eligibility Criteria
- This subject consent data table contains subject IDs and consent group information.
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs.
- This subject phenotype table informs of subject's sex, primary disease, case-control status for schizophrenia or bipolar disorder, and genetically determined ancestry.
- This sample attributes table informs of body site where sample was collected, sample analyte type, sample tumor status, sample histology, whether 30X mean coverage was achieved in the sample during sequencing, and site where sequencing took place.
Similar models
This sample attributes table informs of body site where sample was collected, sample analyte type, sample tumor status, sample histology, whether 30X mean coverage was achieved in the sample during sequencing, and site where sequencing took place.
- StudyEvent: SEV1
- Eligibility Criteria
- This subject consent data table contains subject IDs and consent group information.
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs.
- This subject phenotype table informs of subject's sex, primary disease, case-control status for schizophrenia or bipolar disorder, and genetically determined ancestry.
- This sample attributes table informs of body site where sample was collected, sample analyte type, sample tumor status, sample histology, whether 30X mean coverage was achieved in the sample during sequencing, and site where sequencing took place.
C1299222 (UMLS CUI [1,2])
C1518422 (UMLS CUI [1,2])
C0007634 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C0449560 (UMLS CUI [1,4])
C1292533 (UMLS CUI [1,5])
C4743987 (UMLS CUI [1,2])
C3816446 (UMLS CUI [1,3])
Aucun commentaire